Dupont Capital Management Corp Has $821,000 Holdings in Nevro Corp. (NVRO)
Dupont Capital Management Corp raised its stake in Nevro Corp. (NYSE:NVRO) by 22.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,029 shares of the medical equipment provider’s stock after acquiring an additional 1,677 shares during the period. Dupont Capital Management Corp’s holdings in Nevro Corp. were worth $821,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. UBS Asset Management Americas Inc. raised its holdings in shares of Nevro Corp. by 171.4% during the 1st quarter. UBS Asset Management Americas Inc. now owns 11,397 shares of the medical equipment provider’s stock worth $1,068,000 after buying an additional 7,197 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Nevro Corp. during the 1st quarter worth $237,000. Teachers Advisors LLC raised its holdings in shares of Nevro Corp. by 2.0% during the 1st quarter. Teachers Advisors LLC now owns 43,608 shares of the medical equipment provider’s stock worth $4,086,000 after buying an additional 873 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Nevro Corp. by 5.4% during the 1st quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock worth $760,000 after buying an additional 418 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Nevro Corp. by 5.4% during the 1st quarter. Vanguard Group Inc. now owns 1,934,593 shares of the medical equipment provider’s stock worth $181,271,000 after buying an additional 98,555 shares in the last quarter.
Nevro Corp. (NYSE NVRO) opened at $74.77 on Friday. Nevro Corp. has a fifty-two week low of $65.82 and a fifty-two week high of $99.63. The company has a quick ratio of 8.73, a current ratio of 8.78 and a debt-to-equity ratio of 0.59.
Nevro Corp. (NYSE:NVRO) last issued its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Nevro Corp. had a negative return on equity of 17.27% and a negative net margin of 14.09%. The business had revenue of $82.26 million during the quarter, compared to analysts’ expectations of $80.50 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The business’s revenue for the quarter was up 35.0% compared to the same quarter last year. analysts anticipate that Nevro Corp. will post -1.27 EPS for the current fiscal year.
A number of equities analysts have recently commented on NVRO shares. Morgan Stanley boosted their price target on Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, August 8th. Northland Securities reissued a “buy” rating and set a $96.00 price target on shares of Nevro Corp. in a report on Tuesday. Canaccord Genuity reissued a “buy” rating and set a $120.00 price target on shares of Nevro Corp. in a report on Sunday, October 8th. Zacks Investment Research cut Nevro Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, TheStreet raised Nevro Corp. from a “d+” rating to a “c-” rating in a report on Monday, November 6th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Nevro Corp. presently has a consensus rating of “Hold” and a consensus price target of $100.00.
In other Nevro Corp. news, Director Michael F. Demane sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $93.50, for a total value of $467,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 290,907 shares of company stock valued at $24,670,065. Insiders own 12.10% of the company’s stock.
Nevro Corp. Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO).
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.